Skip to content

NAGE NAGE Additional Paid-In Capital

Additional Paid-In Capital at other companies

eXoZymes Inc. Common Stock logo
eXoZymes Inc. Common StockEXOZ
$25M+10.2%
Lifevantage Corporation logo
Lifevantage CorporationLFVN
$138.73M-0.2%
Biote Corp. logo
Biote Corp.BTMD
$0
NuSkin Enterprises logo
NuSkin EnterprisesNUS
$613.89M-1.5%
USANA Health Sciences logo
USANA Health SciencesUSNA
$84.73M+13.2%
BellRing Brands logo
BellRing BrandsBRBR
$52M+37.2%

Other financials

Income statement

See full
Revenue$31.5M+3.3%
Gross profit$20.0M+3.3%
Operating income$1.6M-67.0%
Net income$6.3M+24.8%
EPS (diluted)$0.07+16.7%

Balance sheet

See full
Cash & equivalents$66.5M+19.7%
Total debt$2.6M-26.9%
Total equity$82.3M+48.8%
Total assets$114.3M+40.6%

Cash flow

See full
Operating cash flow-$1.2M-115%

Valuation

See full
Market cap$254.07M-74.9%
Enterprise value$190.09M-79.7%
P/E13.6×-43.5×
P/S-6.8×

Profitability

See full
Gross margin64.3%+1.8pp
Operating margin10%-2.2pp
Net margin14.3%+1.2pp
FCF margin-70.4%

Returns & leverage

See full
Return on equity27.1%-6.4pp
Debt / equity0.0×
Current ratio4.6×+0.9×

Where this comes from

Reported directly by NAGE in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: NAGE’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about NAGE's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NAGE's additional paid-in capital?
NAGE (NAGE) reported additional paid-in capital of $240.46M in Q1 2026.
How has NAGE's additional paid-in capital changed year-over-year?
NAGE's additional paid-in capital increased by 3.6% year-over-year, from $232.12M to $240.46M.
What is the long-term trend for NAGE's additional paid-in capital?
Over 4 years (2021 to 2025), NAGE's additional paid-in capital has grown at a 4.7% compound annual growth rate (CAGR), from $200.61M to $240.99M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.